These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16330948)

  • 1. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
    Esposito NN; Hunt JL; Bakker A; Jones MW
    Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
    Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
    Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.
    Croce S; Ribeiro A; Brulard C; Noel JC; Amant F; Stoeckle E; Devouassoux-Shisheborah M; Floquet A; Arnould L; Guyon F; Mishellany F; Garbay D; Cuppens T; Zikan M; Leroux A; Frouin E; Duvillard P; Terrier P; Farre I; Valo I; MacGrogan GM; Chibon F
    Mod Pathol; 2015 Jul; 28(7):1001-10. PubMed ID: 25932961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.
    Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
    Schwetye KE; Pfeifer JD; Duncavage EJ
    Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
    Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
    Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
    Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
    Quade BJ
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Criteria for risk stratification of vulvar and vaginal smooth muscle tumors: a follow-up study with application to leiomyoma variants, smooth muscle tumors of uncertain malignant potential, and leiomyosarcomas.
    Swanson AA; Howitt BE; Schoolmeester JK
    Hum Pathol; 2020 Sep; 103():83-94. PubMed ID: 32687944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
    Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
    Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
    Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O
    Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
    Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
    PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
    Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
    Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
    de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
    Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
    Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
    Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
    Shanes ED; Friedman LA; Mills AM
    Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.